Literature DB >> 5919504

Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man.

G A Ellard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 5919504      PMCID： PMC1510771          DOI： 10.1111/j.1476-5381.1966.tb01823.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN： 0366-0826


× No keyword cloud information.
  13 in total

1.  Excretion products of 4:4'-diaminodiphenyl sulfone.

Authors:  S R BUSHBY; A J WOIWOD
Journal:  Am Rev Tuberc       Date:  1955-07

2.  The treatment of leprosy with diaminodiphenyl sulphoxide: a progress report.

Authors:  T F DAVEY; A M KISSAUN; G MONETA
Journal:  Lepr Rev       Date:  1957-04       Impact factor: 0.537

3.  [4, 4'-Diaminodiphenylsulfoxide in the treatment of leprosy].

Authors:  P LAVIRON; L LAURET; P KERBASTARD; C JARDIN
Journal:  Bull Acad Natl Med       Date:  1957 Mar 5-12       Impact factor: 0.144

4.  Radioactive tracer studies on uptake of di-amino-diphenyl-sulphone by leprosy patients.

Authors:  K R CHATTERJEE; R K PODDAR
Journal:  Proc Soc Exp Biol Med       Date:  1957-01

5.  The chemotherapy of leprosy.

Authors:  S R BUSHBY
Journal:  Pharmacol Rev       Date:  1958-03       Impact factor: 25.468

6.  The identification of the major diazotizable metabolite of 4:4'-diaminodiphenyl sulphone in rabbit urine.

Authors:  S R BUSHBY; A J WOIWOD
Journal:  Biochem J       Date:  1956-07       Impact factor: 3.857

7.  Experience with "avlosulfon" soluble.

Authors:  T F DAVEY
Journal:  Lepr Rev       Date:  1956-01       Impact factor: 0.537

8.  [Six months of antileprous treatment in South Vietnam with 4,4'-diaminodiphenylsulfoxide and 4,4'-diethoxythiocarbanilide].

Authors:  N P BUU-HOI
Journal:  Bull Acad Natl Med       Date:  1955 May 3-10       Impact factor: 0.144

9.  Studies in sulphone therapy.

Authors:  J LOWE
Journal:  Lepr Rev       Date:  1952-01       Impact factor: 0.537

10.  Metabolism and excretion of di(p-aminophenyl) sulphoxide in different animal species.

Authors:  A A LEVI; G A SNOW
Journal:  Br J Pharmacol Chemother       Date:  1960-03
View more
  11 in total

1.  Activity of derivatives and analogs of dapsone against Mycobacterium leprae.

Authors:  L Levy
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

2.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

3.  Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

Authors:  R A Ahmad; H J Rogers
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of dapsone.

Authors:  J Zuidema; E S Hilbers-Modderman; F W Merkus
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

Review 5.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  Acetylation polymorphism and leprosy.

Authors:  L C Eze; A N Okpogba; A U Ogan
Journal:  Biochem Genet       Date:  1990-02       Impact factor: 1.890

7.  The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.

Authors:  M D Coleman; L E Rhodes; A K Scott; J L Verbov; P S Friedmann; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

8.  A rapid method for determination of acetylation phenotype using dapsone.

Authors:  P A Philip; M S Roberts; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  N-hydroxylation of 4,4'-diaminodiphenylsulphone (Dapsone) by liver microsomes, and in dogs and humans.

Authors:  H Uehleke; S Tabarelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

10.  Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.

Authors:  Taysa Ribeiro Schalcher; Rosivaldo S Borges; Michael D Coleman; João Batista Júnior; Claudio G Salgado; Jose Luiz F Vieira; Pedro R T Romão; Fabio R Oliveira; Marta Chagas Monteiro
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.